

1 **Performance characteristics of a high throughput automated transcription mediated amplification**
2 **test for SARS-CoV-2 detection**

3 Jimmykim Pham^a, Sarah Meyer^a, Catherine Nguyen^a, Analee Williams^a, Melissa Hunsicker^a, Ian
4 McHardy^b, Inessa Gendlina^c, D. Yitzchak Goldstein^c, Amy S. Fox^c, Angela Hudson^a, Paul Darby^a, Paul
5 Hovey^a, Jose Morales^a, James Mitchell^a, Karen Harrington^a, Mehrdad Majlessi^a, Joshua Moberly^a, Ankur
6 Shah^a, Andrew Worlock^a, Marion Walcher^a, Barbara Eaton^a, Damon Getman^{a†}, Craig Clark^a

7 ^aHologic Inc. 10210 Genetic Center Dr, San Diego CA 92121

8 ^bScripps Health, Microbiology Laboratory, San Diego CA 92121

9 ^cMontefiore Medical Center, Department of Pathology, Bronx, NY 10458

10 [†]Corresponding Author

11

12 **ABSTRACT (210 words)**

13 The COVID-19 pandemic caused by the new SARS-CoV-2 coronavirus has imposed severe challenges on
14 laboratories in their effort to achieve sufficient diagnostic testing capability for identifying infected
15 individuals. In this study we report the analytical and clinical performance characteristics of a new, high-
16 throughput, fully automated nucleic acid amplification test system for the detection of SARS-CoV-2. The
17 assay utilizes target capture, transcription mediated amplification, and acridinium ester-labeled probe
18 chemistry on the automated Panther System to directly amplify and detect two separate target sequences in
19 the ORF1ab region of the SARS-CoV-2 RNA genome. The probit 95% limit of detection of the assay was
20 determined to be 0.004 TCID₅₀/ml using inactivated virus, and 25 c/ml using synthetic *in vitro* transcript
21 RNA targets. Analytical sensitivity (100% detection) was confirmed to be 83 – 194 c/ml using three
22 commercially available SARS-CoV-2 nucleic acid controls. No cross reactivity or interference was observed
23 with testing six related human coronaviruses, as well as 24 other viral, fungal, and bacterial pathogens, at
24 high titer. Clinical nasopharyngeal swab specimen testing (N=140) showed 100%, 98.7%, and 99.3%
25 positive, negative, and overall agreement, respectively, with a validated reverse transcription PCR NAAT for
26 SARS-CoV-2 RNA. These results provide validation evidence for a sensitive and specific method for
27 pandemic-scale automated molecular diagnostic testing for SARS-CoV-2.

28

29 Abstract Word Count: 210

30 Body Word Count: 2114

31 Number of Tables: 4 (1 Supplemental)

32 Number of Figures: 3 (1 Supplemental)

33 Number of references: 18

34

35 Key Words: SARS-CoV-2, automation, high throughput, Aptima, TMA

36

37 Conflict of Interest Statement

38 All authors except I. McHardy, I. Gendlina, D.Y. Goldstein, and A.S. Fox are scientists employed by
39 Hologic Inc., the manufacturer of the diagnostic test systems used in this study. IM, IG, DYG and ASF
40 declare no conflicts of interests.

41 Funding Statement

42 This study was funded by Hologic Inc.

43

44 Running Title: High throughput automated TMA test for SARS-CoV-2

45

46 **INTRODUCTION**

47 Coronavirus disease-19 (COVID19) is a novel respiratory illness caused by severe acute respiratory
48 syndrome coronavirus 2 (SARS-CoV-2), a novel *Sarbecovirus* that emerged from the region of Wuhan,
49 China in late 2019 (1). People with COVID-19 experience mild to severe respiratory symptoms including
50 fever, cough and shortness of breath or difficulty breathing (2), although some individuals experience no
51 symptoms at all (3).

52 The COVID-19 pandemic has occurred across all continents, adding more than 100,000 new SARS-CoV-
53 2 cases globally each day (4,5). As communities begin reopening and relaxing quarantine measures, there
54 is the potential risk for an upsurge in cases and rates of viral transmission. The availability of validated
55 high-throughput diagnostic tests is therefore essential for rapidly and efficiently informing patient
56 management decisions, implementing hospital infection prevention practices, and for guiding public
57 health responses to wide-scale infection control measures to reduce transmission in populations.

58 To meet the need for pandemic-scale diagnostic testing, we have developed and validated a high-
59 throughput, fully automated nucleic acid amplification test (NAAT) for direct amplification and detection
60 of SARS-CoV-2 RNA from specimens of infected individuals. The assay employs target capture,
61 transcription mediated amplification (TMA) and acridinium ester-labeled probe chemistries to enable a
62 sample-to-result solution for detection of two different conserved target regions within the ORF1ab
63 region of the SARS-CoV-2 genome. Herein, we describe the analytical and clinical performance
64 characteristics of the assay.

65

66 **MATERIALS AND METHODS**

67 **Transcription Mediated Amplification Test for SARS-CoV-2.** The Aptima® SARS-CoV-2 assay
68 utilizes magnetic bead-based target capture, isothermal TMA of RNA, and dual kinetic acridinium ester-
69 labeled probe hybridization for the isolation, amplification, and detection of an internal process control
70 RNA, and two unique sequences within the ORF1ab region of the SARS-CoV-2 viral genome. The assay
71 is performed on the automated Panther® and Panther Fusion® instruments (both from Hologic Inc, San
72 Diego, USA), and received FDA Emergency Use Authorization (EUA) on May 14, 2020. It is intended
73 for the qualitative detection of SARS-CoV-2 RNA isolated and purified from nasopharyngeal (NP) swab,
74 nasal swab (NS), mid-turbinate and oropharyngeal (OP) swab, NP wash/aspirate, or nasal aspirate
75 specimens, obtained from individuals meeting COVID-19 clinical and/or epidemiological criteria. Sample
76 input volume is 0.5 ml, with continuous sample and reagent loading access, automated RNA extraction,
77 amplification, detection, and results reporting. Time to first result is 3 h 30 min, with a capacity of
78 approximately 1,025 results per 24 h per instrument system.

79 **Comparison Assay.** The validated EUA Panther Fusion SARS-CoV-2 reverse transcription PCR (RT-
80 PCR) assay (Hologic Inc.) was used as a comparator assay for clinical performance studies. This assay
81 was performed as previously described (6).

82

83

84 **Analytical Performance**

85 **Limit of Detection.** The analytical sensitivity of the SARS-CoV-2 TMA assay was assessed using 2 lots
86 of reagents to test 60 replicates each of dilution panels containing cultured SARS-CoV-2 virus strain
87 USA-WA1/2020 (BEI Resources, Manassas, VA) and diluted in Aptima specimen transport medium
88 (STM) matrix to a range of 0.03 to 0.0003 tissue culture infectious dose 50 per ml (TCID₅₀/ml). Also
89 tested were replicates (n = 43 to 60) of panels consisting of two *in vitro* transcribed (IVT) RNA targets,
90 corresponding to two unique target sequences within the ORF1ab region of the SARS-CoV-2 RNA
91 genome, diluted in STM. Assay positivity for both studies was determined using a pre-defined cutoff
92 value of 560 kilo relative light units (kRLU). Results were analyzed by probit analysis (normal model) to
93 determine the 95% limit of detection (LOD). Analytical sensitivity was confirmed by testing 20 replicates
94 each of SARS-CoV-2 virus diluted in four specimen matrices (pooled NP swab, STM, saline and Liquid
95 Amies transport medium (Copan, Murrieta, CA)) at 0.003 TCID₅₀/ml for NP swab, STM and saline, and
96 0.003 and 0.01 TCID₅₀/ml for Liquid Amies.

97 **Analytical Specificity/Interference.** Analytical specificity of the SARS-CoV-2 TMA assay was
98 determined by evaluating assay cross-reactivity and interference using 30 non-target microorganisms (17
99 viral species, including 6 non - SARS-CoV-2 coronaviruses, 11 bacterial species, and 2 fungal species;
100 N=3 replicates each) at the highest titer achievable. Thirty NP swab specimens obtained from consented
101 asymptomatic donors were also tested to represent diverse microbial flora in the human respiratory tract.
102 Interference by high-titer non-target organisms was assessed by testing of 3 replicates of each organism in
103 the presence of low titer (0.03 TCID₅₀/ml) SARS-CoV-2 virus. Cross reactivity by high-titer non-target
104 organisms was assessed in the absence of SARS-CoV-2 virus.

105 **SARS-CoV-2 Commercial Control Panel Testing.** Stock SARS-CoV-2 control panel materials from
106 three commercial suppliers (Exact Diagnostics (Fort Worth, TX) SARS-CoV-2 Standard, cat no.
107 COV019; SeraCare (Milford, MA) AccuPlex SARS-CoV-2 Verification Panel, cat no. 0505-0126; and
108 ZeptoMetrix (Buffalo, NY) SARS-CoV-2 External Run Control cat no. NATSARS(COV2)-

109 ERC0831042) were diluted in STM to 6 concentrations ranging from 833 to 8 copies per ml (c/ml) and
110 multiple replicates (n = 20 to 40) were tested with the SARS-CoV-2 TMA assay. The control panels were
111 also tested with the SARS-CoV-2 RT-PCR assay on the automated Panther Fusion platform.

112 **Clinical Performance**

113 **Specimen Collection.** Residual de-identified NP swab samples were collected by standard methods from
114 140 symptomatic patients at two different US clinical sites (San Diego, CA and The Bronx, NY).
115 Specimens were transported to the laboratory and tested with the SARS-CoV-2 TMA assay and the
116 Fusion SARS CoV-2 RT-PCR assay. An additional clinical sample set consisting of paired NP swab, OP
117 swab and NS specimens were collected from 38 patients; complete sets (containing all three specimen
118 types) were obtained from 35 patients. NS samples were collected first by inserting the swab into the
119 subject's nostril past the inferior turbinate, approximately 3 cm, twisting the swab in mid-turbinate area
120 for 3 to 5 seconds and placing the swab into a tube of STM. OP swab samples were collected immediately
121 following NS samples by swabbing the posterior pharynx for 3-5 seconds and placing the swab into a
122 specimen tube. Samples were frozen and shipped to Hologic (San Diego, CA) for testing.

123 **RESULTS**

124 Data for the analytical sensitivity determination of the SARS-CoV-2 TMA assay are shown in **Figure 1**.
125 Using a pre-determined cutoff value of 560 kRLU, the assay yielded 100% positivity at a concentration of
126 0.01 TCID₅₀/ml of SARS-CoV-2 virus and at 100 c/ml of SARS-CoV-2 IVT RNA targets. Using probit
127 analysis, the 95% limit of detection was determined to be 0.004 TCID₅₀/ml (95% CI: 0.003 – 0.007) for
128 SARS-CoV-2 virus, and 25.4 c/ml (95% CI: 16.9 - 50.5) for ORF1ab IVT RNA targets. Analytical
129 sensitivity for the assay was confirmed by testing SARS-CoV-2 virus in 4 specimen matrices (pooled NP
130 swab specimens, STM, saline, and Liquid Amies transport medium) at 0.003 TCID₅₀/ml. All specimen
131 matrices yielded 95% positivity (19/20 replicates detected) at this concentration, except Liquid Amies
132 transport medium, which was 85% (17/20) positive at 0.003 TCID₅₀/ml and 100% (20/20) positive at 0.01
133 TCID₅₀/ml (**Table 1**).

134 Analytical specificity of the SARS-CoV-2 TMA assay was determined by evaluating assay cross-
135 reactivity and interference using 30 non-target viral, bacterial and fungal microorganisms at the highest
136 titer achievable, as well as in 30 NP swab specimens obtained from consented asymptomatic donors at
137 low risk of SARS-CoV-2 infection. As shown in the **Supplemental Table**, none of the microorganisms or
138 NP swab specimens tested caused cross-reactivity in the absence of SARS-CoV-2 target or interfered with
139 TMA detection in the presence of SARS-CoV-2 spiked at 0.03 TCID₅₀/ml.

140 The clinical accuracy of the SARS-CoV-2 TMA assay was compared to the SARS-CoV-2 RT-PCR assay
141 using 140 patient NP swab specimens (**Table 2**). This analysis resulted in positive, negative, and overall
142 agreements of 100% (95%CI: 94.3% - 100%), 98.7% (95%CI: 92.9% - 99.8%), and 99.3% (95%CI:
143 96.1% - 99.3%), respectively. Clinical performance of the SARS-CoV-2 TMA assay was also assessed by
144 testing sets of NP swabs, OP swabs, and nasal swabs co-collected from 35 symptomatic patients
145 suspected of being infected with SARS-CoV-2. **Figure 2** shows the SARS-CoV-2 TMA assay had 100%
146 positive and negative agreements of the NP swab specimens with the co-collected OP swab and nasal
147 swab specimens. Similar results were obtained for the paired specimen sets using the SARS-CoV-2 RT-
148 PCR assay (**Supplemental Figure**).

149 SARS-CoV-2 control panel materials from three commercial suppliers (Exact Diagnostics, SeraCare,
150 ZeptoMetrix) were evaluated by building dilution panels of each control material and testing multiple
151 replicates with both the SARS-CoV-2 TMA assay and the SARS-CoV-2 RT-PCR assay (**Table 3**). Both
152 assays yielded similar results. For the Exact Diagnostics SARS-CoV-2 control, the TMA and RT-PCR
153 assays each had 100% detection down to 83 c/ml (N=40 each). For the SeraCare SARS-CoV-2 control,
154 the TMA assay was 100% at 83 c/ml (N=20) while the RT-PCR assay was 90% at 83 c/ml and 100% at
155 194 c/ml (N=20 for both). The SARS-CoV-2 TMA assay (N=37) and the SARS-CoV-2 RT-PCR assay
156 (N=40) were both 100% reactive at 194 c/ml using the ZeptoMetrix control material.

157

158 **DISCUSSION**

159 The availability of large-scale diagnostic testing for SARS-CoV-2 addresses a current critical need for
160 identifying the prevalence and spread of the virus in populations and for guiding public health policies
161 and interventions to minimize incident infections. This study describes the performance characteristics of
162 a new high-throughput isothermal TMA NAAT that employs a complete sample-to-result automation
163 system to maximize sample testing throughput in clinical laboratories. The analytical performance data
164 demonstrates the assay is highly sensitive and specific for detection of viral SARS-CoV-2 RNA and has
165 high clinical agreement (100% positive agreement, 98.7% negative agreement) with a EUA validated RT-
166 PCR assay for SARS-CoV-2 RNA.

167 The unprecedented need for SARS-CoV-2 testing has resulted in national shortages in sample collection
168 materials including VTM, prompting the CDC and FDA to recommend optional specimen collection
169 media, such as saline and Liquid Amies (7, 8). To ensure comparable performance across various
170 collection media, we evaluated analytical sensitivity of the SARS-CoV-2 TMA assay in NP swab matrix
171 (NP swabs collected in VTM), STM, saline, and Liquid Amies transport medium using inactivated
172 SARS-CoV-2 virus. NP swab matrix, Aptima STM, and saline demonstrated 95% detection at 0.003
173 TCID₅₀/ml, whereas Liquid Amies showed slightly lower sensitivity at 0.01 TCID₅₀/ml. Despite this small
174 difference in analytical sensitivity, these results suggest that all media are acceptable for use for clinical
175 sample collection.

176 NP swab specimens have been considered the gold standard sampling method for respiratory virus
177 infection (9) as it has been reported that nasal swab or OP swab samples may have a slightly lower
178 sensitivity compared to NP swabs (10, 11). However, given the challenges of collection device shortages
179 for SARS-CoV-2 diagnosis, particularly NP swabs and VTM, the use of nasal swab and OP swab as
180 alternate samples for diagnosis of SARS-CoV-2 has been evaluated. The CDC recently removed NP swab
181 as the “preferred” sample type from their sample collection guidelines (7) and others have reported
182 comparable performance of NS and OP swabs for the diagnosis of SARS-CoV-2 (12-15). Our data shows

183 strong agreement between SARS-CoV-2 detection from NS and OP swabs compared to paired NP swab
184 samples for the SARS-CoV-2 TMA and SARS-CoV-2 RT-PCR assays. We did observe for one patient
185 positive NP and nasal swab results, but negative results in the paired OP swab, however overall the data
186 indicate that both NS and OP swab specimens are adequate sample types for diagnosis of SARS-CoV-2.

187 The performance of other SARS-CoV-2 NAATs that have received Emergency Use Authorization has
188 been characterized using commercially available inactivated virus preparations (e.g., BEI Resources,
189 Manassas, VA) or synthetic RNA quality control materials. Our evaluation of three different external
190 RNA control materials demonstrated comparable analytical sensitivity with both the SARS-CoV-2 TMA
191 assay and the SARS-CoV-2 RT-PCR assay, with LOD values between 83 c/ml – 194 c/ml. These
192 analytical sensitivity values correlate with previously reported LOD values by Zhen *et al* (16). However,
193 using LOD values as determined by external control material to assess or compare assay performance
194 warrants some caution as different control materials may give considerably different results for the
195 absolute LOD value (16) and the reported RNA or DNA stock concentrations of these materials may
196 differ from true concentrations (17).

197 Limitations of this study include the small number of clinical specimens available for testing, and the
198 absence of discordant result resolution by testing with a third assay. The paired specimen testing (NS and
199 OP) included only 35 patients (14 of which were positive). The specimens that were included did span a
200 typical clinical titer range for the virus (SARS-CoV-2 RT-PCR Ct values ranged from 14.5 to 37.1).
201 Additional clinical data should be collected to more fully assess and compare performance between these
202 sample types.

203 In summary, the SARS-CoV-2 TMA assay is highly sensitive and specific and provides an automated
204 high-throughput testing solution for large-scale diagnostic testing for the virus. The assay system is able
205 to process and generate results for > 1,000 samples per day enabling medical centers, reference
206 laboratories and public health laboratories to efficiently process and analyze very high volumes of
207 specimens for the detection of SARS-CoV-2 RNA (18).

208 **REFERENCES**

- 209 1. WHO. Q&A on coronaviruses (COVID-19). World Health Organization, 2020.
210 <https://www.who.int/news-room/q-a-detail/q-a-coronaviruses>. Accessed May 17, 2020.
- 211 2. CDC. Coronavirus Disease 2019 (COVID-19) Symptoms of Coronavirus. Centers for Disease
212 Control and Prevention, 2020. [https://www.cdc.gov/coronavirus/2019-ncov/symptoms-](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html)
213 [testing/symptoms.html](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html). Accessed May 17, 2020.
- 214 3. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, Hayashi K, Kinoshita R, Yang Y, Yuan
215 B, Akhmetzhanov AR, Linton NM. 2020. Estimation of the asymptomatic ratio of novel
216 coronavirus infections (COVID-19). *Int J Infect Dis* 94:154-155.
- 217 4. WHO. Coronavirus Disease (COVID-19) Dashboard. World Health Organization, 2020.
218 <https://covid19.who.int/>. Accessed June 13, 2020.
- 219 5. JHU CSSE. Rate of Positive Tests in the US and States Over Time. COVID-19 Data Repository
220 by the Center for Systems Science and Engineering at Johns Hopkins University, 2020.
221 <https://coronavirus.jhu.edu/testing/individual-states>. Accessed June 13, 2020.
- 222 6. Zhen W, Manji R, Smith E, Berry GJ. 2020. Comparison of Four Molecular In Vitro Diagnostic
223 Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens. *J Clin Micro*
224 <https://doi.org/10.1128/JCM.00743-20> [Epub ahead of print].
- 225 7. CDC. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-
226 19. <https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html>.
227 Accessed June 13, 2020.
- 228 8. FDA. FAQs on Testing for SARS-CoV-2. [https://www.fda.gov/medical-devices/emergency-](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-testing-sars-cov-2#whatif)
229 [situations-medical-devices/faqs-testing-sars-cov-2#whatif](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-testing-sars-cov-2#whatif). Accessed Jun 10, 2020
- 230 9. Ginocchio CC, McAdam AJ. 2011. Current Best Practices for Respiratory Virus Testing. *J Clin*
231 *Microbiol* 49(9Suppl):S44-S48.
- 232 10. Lambert SB, Whiley DM, O'Neill NT, Andrews EC, Canavan FM, Bletchly C, Siebert DJ, Sloots
233 TP, Nissen MD. 2008. Comparing nose-throat swabs and nasopharyngeal aspirates collected from

- 234 children with symptoms for respiratory virus identification using real-time polymerase chain
235 reaction. *Pediatrics* 122: e615–e620.
- 236 11. Meerhoff TJ, Houben ML, Coenjaerts FE, Kimpfen JL, Hofland RW, Schellevis F, Bont LJ. 2010.
237 Detection of multiple respiratory pathogens during primary respiratory infection: nasal swab
238 versus nasopharyngeal aspirate using real-time polymerase chain reaction. *Eur J Clin Microbiol*
239 *Infect Dis* 29: 365-371.
- 240 12. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones
241 TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmman R,
242 Zwirgmaier K, Drosten C, Wendtner C. 2020. Virological assessment of hospitalized patients
243 with COVID-2019. *Nature* 581(7809):465-469.
- 244 13. Berenger, B.M, Fonseca, K, Schneider, A, Hu, J, Zelyas, N. 2020. Sensitivity of Nasopharyngeal,
245 Nasal and Throat Swab for the Detection of SARS-CoV-2. medRxiv
246 <https://doi.org/10.1101/2020.05.05.20084889>. Accessed 01Jun2020.
- 247 14. Péré H, Podglajen I, Wack M, Flamarion E, Mirault T, Goudot G, Hauw-Berlemont C, Le L,
248 Caudron E, Carrabin S, Rodary J, Ribeyre T, Bélec L, Veyer D. 2020. Nasal Swab Sampling for
249 SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage. *J Clin*
250 *Microbiol* 58(6):e00721-20.
- 251 15. Wehrhahn MC, Robson J, Brown S, Bursle E, Byrne S, New D, Chong S, Newcombe JP,
252 Siversten T, Hadlow N. 2020. Self-collection: An appropriate alternative during the SARS-CoV-2
253 pandemic. *J Clin Virol* 128:104417 <https://doi.org/10.1016/j.jcv.2020.104417> [Epub ahead of
254 print]
- 255 16. Smith E, Zhen W, Manji R, Schron D, Duong S, Berry GJ. 2020. Analytical and Clinical
256 Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection. bioRxiv
257 <https://doi.org/10.1101/2020.05.14.097311>. Accessed 10Jun2020.


258 17. Jue E, Ismagilov RF. 2020. Commercial stocks of SARS-CoV-2 RNA may report low
259 concentration values, leading to artificially increased apparent sensitivity of diagnostic assays.
260 medRxiv <https://doi.org/10.1101/2020.04.28.20077602> . Accessed 10Jun2020.

261 18. Craney AR, Velu P, Satlin MJ, Fauntleroy KA, Callan K, Robertson A, LaSpina M, Lei B, Chen
262 A, Alston T, Rozman A, Loda M, Rennert H, Cushing M, Westblade, LF. 2020. Comparison of
263 Two High-Throughput Reverse Transcription-Polymerase Chain Reaction Systems for the
264 Detection of Severe Acute Respiratory Syndrome Coronavirus 2. J Clin Micro
265 <https://doi.org/10.1128/JCM.00890-20> [Epub ahead of print]

266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285

286

287



Panel	Concentration	N	Pos (n)	% Pos
orflab IVT Targets (copies/ml)	3	60	28	47
	10	60	55	92
	30	60	55	92
	100	60	60	100
	300	58	58	100
	1000	43	43	100
SARS-CoV-2 (TCID ₅₀ /ml)	0.0003	55	11	20
	0.001	60	38	63
	0.003	60	53	88
	0.01	60	60	100
	0.03	60	60	100

288

289

290 **Figure 1.** Analytical sensitivity of automated Aptima SARS-CoV-2 TMA assay for detection of SARS-CoV-2 Open Reading Frame 1ab (orf1ab)
 291 RNA. IVT, *in vitro* RNA transcript; TCID₅₀, Tissue Culture Infectious Dose 50%.

292

A.

		Nasopharyngeal Swab		
		+	-	Total
Oropharyngeal Swab	+	14	0	14
	-	0	21	21
	Total	14	21	35
Nasal Swab	+	14	0	14
	-	0	21	21
	Total	14	21	35
Overall Agreements		100.0%	(90.1% - 100.0%)	
Positive Agreements		100.0%	(78.5% - 100.0%)	
Negative Agreements		100.0%	(84.5% - 100.0%)	

B.





Figure 2. Agreement (A) between 35 sets of co-collected nasopharyngeal swab, oropharyngeal swab, and nasal swab clinical specimens with positive (+) and negative (-) Aptima SARS-CoV-2 TMA assay results. Scatter plot (B) of corresponding Aptima SARS-CoV-2 TMA assay positive and negative kRLU signal for each sample type.

A.

		Nasopharyngeal Swab		
		+	-	Total
OroPharyngeal Swab	+	13	0	13
	-	1	21	22
	Total	14	21	35
Nasal Swab	+	14	0	14
	-	0	21	21
	Total	14	21	35
Overall Agreements		97.1%	(85.5% - 99.5%)	
Positive Agreements		92.9%	(68.5% - 98.7%)	
Negative Agreements		100.0%	(84.5% - 100.0%)	

B.



Supplemental Figure. Agreement (A) between 35 sets of co-collected nasopharyngeal swab, oropharyngeal swab, and nasal swab clinical specimens with positive (+) and negative (-) Panther Fusion SARS-CoV-2 RT-PCR assay results. Scatter plot (B) of RT-PCR Ct values corresponding to Panther Fusion SARS-CoV-2 RT-PCR assay positive samples for each swab type.

Table 1. Confirmation of Aptima SARS-CoV-2 TMA assay limit of detection in different specimen matrices.

Target	Matrix	TCID ₅₀ /ml	n/N (%)	Average kRLU (%CV)
SARS-CoV-2 virus	NP	0	0/0 (0)	278 (2.9)
		0.003	19/20 (95)	908 (17.2)
	STM	0	0/0 (0)	289 (2.2)
		0.003	19/20 (95)	835 (24.4)
	Saline	0	0/0 (0)	288 (2.4)
		0.003	19/20 (95)	876 (24.8)
	Liquid Amies	0	0/0 (0)	286 (1.8)
		0.003	17/20 (85)	877 (24.7)
		0.01	20/20 (100)	1100 (3.9)

STM, Aptima specimen transport medium. kRLU, kilo relative light unit.

Table 2. Agreement analysis (% , (95% confidence interval) between the Aptima SARS-CoV-2 TMA assay and the Panther Fusion SARS-CoV-2 RT-PCR assay for nasopharyngeal swab specimens.

Aptima SARS-CoV-2 TMA Result	Panther Fusion SARS-CoV-2 RT-PCR Result		
	+	-	Total
+	64	1	65
-	0	75	75
Total	64	76	140

Overall Agreement	99.3%	(96.1% - 99.3%)
Positive Agreement	100%	(94.3% - 100%)
Negative Agreement	98.7%	(92.9% - 99.8%)

Table 3. Performance of Aptima SARS-CoV-2 TMA and Panther Fusion SARS-CoV-2 RT-PCR assays for detection of commercially available SARS-CoV-2 controls.

SARS-CoV-2 Control Vendor	Concentration (c/ml)	Aptima SARS-CoV-2 TMA n/N (%)	Panther Fusion SARS-CoV-2 RT-PCR n/N (%)
Exact Diagnostics SARS-CoV-2 Standard	833	40/40 (100)	38/38 (100)
	417	40/40 (100)	39/39 (100)
	194	40/40 (100)	40/40 (100)
	83	40/40 (100)	40/40 (100)
	19	35/39 (90)	30/40 (75)
	8	29/39 (74)	21/40 (53)
SeraCare Accuplex™ SARS-CoV-2 Verification Panel	833	20/20 (100)	20/20 (100)
	417	19/19 (100)	20/20 (100)
	194	19/19 (100)	20/20 (100)
	83	20/20 (100)	18/20 (90)
	19	16/40 (40)	11/40 (28)
	8	7/40 (18)	4/40 (10)
ZeptoMetrics SARS-CoV-2 (recombinant)	833	39/39 (100)	40/40 (100)
	417	40/40 (100)	40/40 (100)
	194	37/37 (100)	40/40 (100)
	83	39/40 (97.5)	32/40 (80)
	19	12/40 (30)	14/40 (35)
	8	12/40 (30)	8/40 (20)

Supplemental Table. Microorganism cross reactivity and interference of the Aptima SARS-CoV-2 TMA assay.

Microorganism	Concentration	SARS-CoV-2 Unspiked			SARS-CoV-2 Spiked ^a		
		N Tested	N Detected	% Detected	N Tested	N Detected	% Detected
No organism Control	N/A	3	0	0	3	3	100
Human coronavirus 229E	1.00E+05 TCID50/ml	3	0	0	3	3	100
Human coronavirus OC43	1.00E+05 TCID50/ml	3	0	0	3	3	100
Human coronavirus HKU1	1.00E+06 c/ml	3	0	0	3	3	100
Human coronavirus NL63	1.00E+04 TCID50/ml	3	0	0	3	3	100
SARS-coronavirus	1.00E+06 c/ml	3	0	0	3	3	100
MERS-coronavirus	1.00E+04 TCID50/ml	3	0	0	3	3	100
Adenovirus	1.00E+05 TCID50/ml	3	0	0	3	3	100
Human Metapneumovirus (hMPV)	1.00E+06 TCID50/ml	3	0	0	3	3	100
Parainfluenza virus 1	1.00E+05 TCID50/ml	3	0	0	3	3	100
Parainfluenza virus 2	1.00E+05 TCID50/ml	3	0	0	3	3	100
Parainfluenza virus 3	1.00E+05 TCID50/ml	3	0	0	3	3	100
Parainfluenza virus 4	1.00E+03 TCID50/ml	3	0	0	3	3	100
Influenza A (H3N2)	1.00E+05 TCID50/ml	3	0	0	3	3	100

Microorganism	Concentration	SARS-CoV-2 Unspiked			SARS-CoV-2 Spiked ^a		
		N Tested	N Detected	% Detected	N Tested	N Detected	% Detected
Influenza B	2.00E+03 TCID50/ml	3	0	0	3	3	100
Enterovirus (e.g. EV68)	1.00E+05 TCID50/ml	3	0	0	3	3	100
Respiratory syncytial virus	1.00E+05 TCID50/ml	3	0	0	3	3	100
Rhinovirus	1.00E+04 TCID50/ml	3	0	0	3	3	100
<i>Chlamydia pneumonia</i>	1.00E+06 IFU/ml	3	0	0	3	3	100
<i>Haemophilus influenzae</i>	1.00E+06 CFU/ml	3	0	0	3	3	100
<i>Legionella pneumophila</i>	1.00E+06 CFU/ml	3	0	0	3	3	100
<i>Mycobacterium tuberculosis</i>	1.00E+06 TCID50/ml	3	0	0	3	3	100
<i>Streptococcus pneumonia</i>	1.00E+06 CFU/ml	3	0	0	3	3	100
<i>Streptococcus pyogenes</i>	1.00E+06 CFU/ml	3	0	0	3	3	100
<i>Bordetella pertussis</i>	1.00E+06 CFU/ml	3	0	0	3	3	100
<i>Mycoplasma pneumoniae</i>	1.00E+06 CFU/ml	3	0	0	3	3	100
<i>Pneumocystis jirovecii</i>	1.00E+06 nuc/ml	3	0	0	3	3	100
<i>Candida albicans</i>	1.00E+06 CFU/ml	3	0	0	3	3	100
<i>Pseudomonas aeruginosa</i>	1.00E+06 CFU/ml	3	0	0	3	3	100

Microorganism	Concentration	SARS-CoV-2 Unspiked			SARS-CoV-2 Spiked ^a		
		N Tested	N Detected	% Detected	N Tested	N Detected	% Detected
<i>Staphylococcus epidermidis</i>	1.00E+06 CFU/ml	3	0	0	3	3	100
<i>Streptococcus salivarius</i>	1.00E+06 CFU/ml	3	0	0	3	3	100
Negative clinical NP swab specimens (N=30 ^b)	N/A	90	0	0	90	90	100

^aSARS-CoV-2 inactivated cultured virus spiked at 0.03 TCID₅₀/ml (3x LoD)

^bEach NP swab specimen was tested in triplicate for a total of 90 replicates in the absence and presence of spiked SARS-CoV-2 inactivated virus.